Goldman Sachs Upgrades Teva Pharma (TEVA) to Conviction Buy

Goldman Sachs analyst Jami Rubin upgraded Teva Pharma (NYSE: TEVA) from Buy to Conviction Buy with a price target of $30.00.

The analyst upgrades the name citing his confusion over the recent underperformance which he believes is a buying opportunity at current levels. The analyst believes the key to the TEVA story is deleveraging and returning to top-line growth in 2020, something he says the company's "has barely missed a beat" on given debt repayments and cost cuts which are ahead of expectations.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $21.54 yesterday.

You May Also Be Interested In

• Coinbase (COIN) PT Raised to $212 at Cantor Fitzgerald
• Snowflake Inc. (SNOW) PT Raised to $405 at Cantor Fitzgerald on Expanding Market Multiples
• Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients